Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 16, 2018, regarding events occurring on April 15, 2018. The filing concerns the 2018 Annual Meeting of Stockholders convened by Protalix Biotherapeutics, Inc., a Delaware corporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance proceedings and does not contain financial performance data.
Material Changes
The primary material event reported is the adjournment of the 2018 Annual Meeting of Stockholders. The meeting was originally held on April 15, 2018, and was adjourned to May 13, 2018, to allow the Company additional time to solicit proxies from stockholders.
Outlook, Risks, and Management Commentary
Management indicated that the adjournment was necessary to secure additional proxy support. The adjournment was approved by a vote of 79,256,545 shares of common stock, with no shares voting against or abstaining, and no broker non-votes. The record date for the meeting remains February 26, 2018. No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- The Annual Meeting was adjourned to May 13, 2018, to solicit additional proxies.
- The adjournment received unanimous approval from shares present (79,256,545 shares).
- The record date for voting remains February 26, 2018.
- The meeting location remains the offices of Horn & Co., Law Offices in Tel Aviv, Israel.